The 1‐year continuation rate and discontinuation factors of vibegron and mirabegron: A retrospective comparative study in a rehabilitation hospital in Japan-Reference-Cited by-同舟云学术

The 1‐year continuation rate and discontinuation factors of vibegron and mirabegron: A retrospective comparative study in a rehabilitation hospital in Japan

Published:2021-05-24 Issue:4 Volume:13 Page:448-455
ISSN:1757-5664
Container-title:LUTS: Lower Urinary Tract Symptoms
language:en
Short-container-title:Lower Urinary Tract Symptoms

Author:

Mukai Shigeto¹,Nomi Masashi²,Yamada Shogo¹,Yanagiuchi Akihiro²³,Sengoku Atsushi²

Affiliation:

1. Department of Pharmacy Hyogo Prefectural Central Rehabilitation Hospital Kobe Japan

2. Department of Urology Hyogo prefectural Central Rehabilitation Hospital Kobe Japan

3. Department of Urology Hyogo Prefectural Nishi‐Harima Rehabilitation Hospital Tatsuno Japan

Publisher

Wiley

Subject

Urology,Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/luts.12391

Reference19 articles.

1. Prevalence of overactive bladder in China, Taiwan and South Korea: Results from a cross-sectional, population-based study

2. National Institute for Health and Care Excellence (NICE).Overview | Lower urinary tract symptoms in men: management | Guidance | NICE. Natl. Inst. Heal. Care Excell. 2015.https://www.nice.org.uk/guidance/cg97. Accessed Jan 2 2021.

3. NICE Guidance - Urinary incontinence and pelvic organ prolapse in women: management

4. Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial

5. Vibegron, a Novel Potent and Selective β 3 -Adrenoreceptor Agonist, for the Treatment of Patients with Overactive Bladder: A Randomized, Double-blind, Placebo-controlled Phase 3 Study

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Adherence to and Persistence with Vibegron in Patients with Overactive Bladder: A Retrospective Claims Analysis;Advances in Therapy;2024-03-23

2. Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial;World Journal of Urology;2024-03-02

3. What is the best first choice oral drug therapy for OAB?;Neurourology and Urodynamics;2024-01-25

4. A Randomized, Double-Blind, Placebo-Controlled, Bridging Study to Evaluate the Efficacy and Safety of Vibegron in Treating Korean Patients With Overactive Bladder;International Neurourology Journal;2023-06-30

5. Rac1 as a Target to Treat Dysfunctions and Cancer of the Bladder;Biomedicines;2022-06-08